Why it matters
The federal government is explicitly funding infrastructure intended to make healthspan a clinically testable and potentially regulatable therapeutic target.
Decision implication
Track biomarkers, endpoint qualification, trial methods, regulatory precedents, and commercialization pathways created by PROSPR.
Who or what is affected
- ARPA-H
- PROSPR teams
- FDA/regulators
- research institutions
- healthspan industry
Evidence and sources
Decision priority: Watch
Source authority: Primary/authoritative · official federal source
Evidence design: Program record
Applicability: Direct
Confidence for the stated claim: High
Freshness: Current
P4L distinguishes the sourced record from interpretation. Program inclusion, participation, funding, proposal status, or a public listing does not by itself establish clinical effectiveness, endorsement, coverage, or scaled adoption unless the cited source specifically establishes it.
For this decision
Researchers · Innovators · Funders/investors · Policymakers
What P4L is watching next
- Milestones
- biomarker validation
- trial recruitment
- regulatory interactions
- published results.
Related proof records
Record provenance
- Last verified
- 2026-09-03
- Source updated
- 2026-02-24
- Revision state
- Version 1.1 records the September 3, 2026 re-verification and clarifies the seven-award count, funding ceiling, milestone contingency, and absence of reported program outcomes.
- Status
- Seven program awards listed · up to $144M over five years · milestone-contingent
- Freshness
- Current
- Version
- 1.1
- Stable ID
- SIG-2026-005